ArticleSkeletal muscle2023
Sarcopenia: investigation of metabolic changes and its associated mechanisms.
Article in Skeletal muscle, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Apparent Saturation of Branched-Chain Amino Acid Catabolism After High Dietary Milk Protein Intake in Healthy Adults.The Journal of clinical endocrinology and metabolism · 2025Trial
- Review
- Physiological responses to mask-associated COFrontiers in public health · 2026Review
- Age-related decline of chaperone-mediated autophagy in skeletal muscle leads to progressive myopathy.Nature metabolism · 2025Article
- Understanding the Metabolic Fingerprint of Muscle Aging.The journal of nutrition, health & aging · 2025Article
- The Role of Methylmalonic Acid in the Risk of Sarcopenia and All-Cause Mortality Among Individuals With Sarcopenia: Evidence From NHANES.Food science & nutrition · 2025Article
- Diabetes and Sarcopenia: Metabolomic Signature of Pathogenic Pathways and Targeted Therapies.International journal of molecular sciences · 2025Review
- Knowledge, attitude, and practice of healthcare professionals toward sarcopenia.Scientific reports · 2025Article
- A review of omics studies in sarcopenia: from molecular mechanisms to hepatic-gut-muscle interactions in chronic liver disease comorbidity.Frontiers in cellular and infection microbiology · 2025Review
- Association of the cardiometabolic index with sarcopenia among U.S. adults: NHANES 2011-2018 findings.PloS one · 2025Article
- Sarcopenia: recent advances for detection, progression, and metabolic alterations along with therapeutic targets.Canadian journal of physiology and pharmacology · 2024Review
- Exploring the Relationship Between Gut Microbiota and Sarcopenia Based on Gut-Muscle Axis.Food science & nutrition · 2024Review
- Unraveling the Evolutionary Diet Mismatch and Its Contribution to the Deterioration of Body Composition.Metabolites · 2024Review
- The causal relationship of human blood metabolites with the components of Sarcopenia: a two-sample Mendelian randomization analysis.BMC geriatrics · 2024Article
- Aging-Related Sarcopenia: Metabolic Characteristics and Therapeutic Strategies.Aging and disease · 2024Review
- Association between F2-Isoprostane Metabolites and Weight Change in Older Women: A Longitudinal Analysis.Gerontology · 2024Article
- A prospective longitudinal cohort study on risk factors for COVID-19 vaccination failure (RisCoin): methods, procedures and characterization of the cohort.Clinical and experimental medicine · 2023Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSarcopenia is one of the most predominant musculoskeletal diseases of the elderly, defined as age-related progressive and generalized loss of muscle mass with a simultaneous reduction in muscle strength and/or function. Using metabolomics, we aimed to examine the association between sarcopenia and the plasma metabolic profile of sarcopenic patients, measured using a targeted HPLC-MS/MS platform.
methodsPlasma samples from 22 (17 men) hip fracture patients undergoing surgery (8 sarcopenic, age 81.4+6.3, and 14 non-sarcopenic, age 78.4±8.1) were analyzed. T test, fold change, orthogonal partial least squares discriminant analysis, and sparse partial least squares discriminant analysis were used for mining significant features. Metabolite set enrichment analysis and mediation analysis by PLSSEM were thereafter performed.
resultsUsing a univariate analysis for sarcopenia z score, the amino acid citrulline was the only metabolite with a significant group difference after FDR correction. Positive trends were observed between the sarcopenia z score and very long-chain fatty acids as well as dicarboxylic acid carnitines. Multivariate analysis showed citrulline, non-esterified fatty acid 26:2, and decanedioyl carnitine as the top three metabolites according to the variable importance in projection using oPLS-DA and loadings weight by sPLS-DA. Metabolite set enrichment analysis showed carnitine palmitoyltransferase deficiency (II) as the highest condition related to the metabolome.
conclusionsWe observed a difference in the plasma metabolic profile in association with different measures of sarcopenia, which identifies very long-chain fatty acids, Carn.DC and citrulline as key variables associated with the disease severity. These findings point to a potential link between sarcopenia and mitochondrial dysfunction and portraits a number of possible biochemical pathways which might be involved in the disease pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.